Pfizer, Inc. (NYSE:PFE) was the target of unusually large options trading on Tuesday. Stock traders bought 1,389 call options on the stock. This represents an increase of approximately 135% compared to the typical volume of 590 call options.

Pfizer (NYSE PFE) traded up 1.29% during mid-day trading on Tuesday, reaching $33.65. The company’s stock had a trading volume of 13,903,621 shares. The firm has a 50 day moving average price of $32.71 and a 200-day moving average price of $33.05. Pfizer has a 1-year low of $29.83 and a 1-year high of $37.39. The company has a market capitalization of $200.82 billion, a PE ratio of 28.32 and a beta of 1.02.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 EPS for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.02. Pfizer had a return on equity of 23.68% and a net margin of 13.76%. The company had revenue of $12.78 billion for the quarter, compared to the consensus estimate of $13.09 billion. During the same quarter in the previous year, the business earned $0.67 EPS. The company’s quarterly revenue was down 1.7% compared to the same quarter last year. On average, equities analysts predict that Pfizer will post $2.55 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 1st. Stockholders of record on Friday, May 12th were paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.85%. The ex-dividend date was Wednesday, May 10th. Pfizer’s dividend payout ratio is presently 108.48%.

Hedge funds have recently bought and sold shares of the company. BlackRock Inc. boosted its position in shares of Pfizer by 2,821.6% in the first quarter. BlackRock Inc. now owns 446,564,230 shares of the biopharmaceutical company’s stock worth $15,276,963,000 after buying an additional 431,279,344 shares during the last quarter. Norges Bank bought a new position in shares of Pfizer during the fourth quarter worth about $1,896,890,000. Russell Investments Group Ltd. bought a new position in shares of Pfizer during the fourth quarter worth about $384,874,000. State Street Corp boosted its position in shares of Pfizer by 3.5% in the fourth quarter. State Street Corp now owns 320,794,199 shares of the biopharmaceutical company’s stock worth $10,419,393,000 after buying an additional 10,838,463 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its position in shares of Pfizer by 22.2% in the first quarter. Massachusetts Financial Services Co. MA now owns 57,581,755 shares of the biopharmaceutical company’s stock worth $1,969,872,000 after buying an additional 10,458,920 shares during the last quarter. 70.80% of the stock is currently owned by institutional investors.

Several equities research analysts have recently commented on the company. Citigroup Inc. cut Pfizer from a “neutral” rating to a “sell” rating and cut their price target for the stock from $38.00 to $31.00 in a research note on Tuesday, May 16th. Jefferies Group LLC set a $34.00 price target on Pfizer and gave the stock a “neutral” rating in a research note on Thursday, March 9th. Sanford C. Bernstein set a $35.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Monday, March 13th. Vetr cut Pfizer from a “buy” rating to a “hold” rating and set a $33.68 price target for the company. in a research note on Monday, March 13th. Finally, Credit Suisse Group set a $38.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Monday, March 13th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company’s stock. Pfizer has an average rating of “Hold” and an average target price of $37.32.

WARNING: This piece was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/06/20/pfizer-target-of-unusually-high-options-trading-pfe-3.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.